Sanofi avoids EU fine over rival vaccine dispute
French pharmaceutical company Sanofi has avoided a potential EU antitrust fine after agreeing to stop disparaging a rival flu vaccine made by CSL Seqirus. The company pledged to halt promotional materials criticizing the competitor through 2030.
Xurve View
Insights:
Xurve View
Sanofi escaped a potential fine of up to 10% of its global annual turnover after European Union regulators accepted its pledge to stop disparaging a rival flu vaccine. The European Commission launched an investigation in June examining promotional practices in France and Germany targeting CSL Seqirus's competing product. The settlement removes a major regulatory overhang for the drugmaker, which agreed to alter its marketing and publish clarifying statements through 2030.
